SCHEMBL4775362

SCHEMBL4775362

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(N(C=O)CC(O)c2ccccn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
ALDH1A1 P00352 4/20 0.35
POLB P06746 2/20 0.35
CYP2D6 P10635 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
CRY1 Q16526 1/20 0.33
CRY2 Q49AN0 1/20 0.33
AGTR1 P30556 1/20 0.33
PER2 O15055 1/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
RECQL P46063 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777314 0.86 GAA (0.38) GAAALDH1A1POLBCYP2D6CRY1
SCHEMBL4777347 0.82 NR1H4 (0.39) GAAALDH1A1POLBCYP2D6SLC6A2
SCHEMBL4771365 0.82 GAA (0.37) GAAALDH1A1POLBCYP2D6CRY1
SCHEMBL4777561 0.79 GAA (0.36) GAAALDH1A1POLBCYP2D6CRY1
SCHEMBL4777570 0.79 GAA (0.43) GAAALDH1A1POLBCRY1CRY2
SCHEMBL4776590 0.78 GAA (0.42) GAAALDH1A1POLBCRY1CRY2
SCHEMBL4775060 0.75 GAA (0.39) GAAALDH1A1POLBMAPTMEN1
SCHEMBL4768221 0.74 GAA (0.37) GAAALDH1A1POLBMAPTMEN1
SCHEMBL5571819 0.74 SLC6A4 (0.42) GAAALDH1A1POLBCYP2D6SLC6A2
SCHEMBL4771056 0.73 GAA (0.37) GAAALDH1A1POLBCYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885ALDH1A1 2159/4885POLB 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.